Foghorn Therapeutics Inc. has described probable global transcription activator SNF2L2 (SMARCA2; BRM) and transcription activator BRG1 (SMARCA4) degradation inducers acting as BRG1- or BRM-associated factor (BAF) complex modulators reported to be useful for the treatment of cancer and viral infection.
Shanghai Meiyue Biotech Development Co. Ltd. has identified MAPK p38 inhibitors reported to be useful for the treatment of cancer, arthritis, psoriasis, systemic lupus erythematosus, diabetes, atherosclerosis and Alzheimer’s disease.
Simcere Zaiming Pharmaceutical Co. Ltd. has synthesized antibody-drug conjugates (ADC) comprising humanized monoclonal antibodies targeting CDH6 covalently linked to a camptothecin analogue through a linker.
Touchstone Innovations Ltd. has disclosed eukaryotic translation initiation factor 2-α kinase 4 (GCN2) inhibitors reported to be useful for the treatment of cancer, myocardial ischemia, diabetic cardiopathy, cardiotoxicity, nonalcoholic fatty liver disease and diabetic retinopathy.
After a nine-month review, the Biden administration is preparing to go where all other U.S. administrations have refused to trod. In releasing a draft framework to help federal agencies decide whether to exercise a federal march-in on patent rights protecting taxpayer-supported drugs and other inventions, including medical devices.
After a nine-month review, the Biden administration is preparing to go where all other U.S. administrations have refused to trod. In releasing a draft framework to help federal agencies decide whether to exercise a federal march-in on patent rights protecting taxpayer-supported drugs and other inventions, including medical devices, the Department of Commerce’s National Institute of Standards and Technology included price as a factor in considering whether a product is “reasonably” available, as required under the 1980 Bayh-Dole Act.
Janssen Pharmaceutica NV had disclosed new pyrrolidinone derivatives acting as NF-κB-inducing kinase (NIK; MAP3K14) inhibitors and reported to be useful for the treatment of cancer.
Kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer have been detailed in a recent GT Apeiron Therapeutics patent.
Research at Nanjing Gritpharma Co. Ltd. has led to the identification of stilbene derivatives acting as aryl hydrocarbon receptor (AhR) agonists. As such, they are reported to be useful for the treatment of allergy, asthma, atherosclerosis, diabetes type 2, infections, osteoporosis, transplant rejection and graft-vs.-host disease.
RSS
